| Literature DB >> 28059088 |
Philip Hinchliffe1, Qiu E Yang2, Edward Portal2, Tom Young3, Hui Li4, Catherine L Tooke1, Maria J Carvalho2, Neil G Paterson5, Jürgen Brem6, Pannika R Niumsup7, Uttapoln Tansawai7, Lei Lei4, Mei Li4, Zhangqi Shen4, Yang Wang4, Christopher J Schofield6, Adrian J Mulholland3, Jianzhong Shen4, Natalie Fey3, Timothy R Walsh2, James Spencer1.
Abstract
The polymixin colistin is a "last line" antibiotic against extensively-resistant Gram-negative bacteria. Recently, the mcr-1 gene was identified as a plasmid-mediated resistance mechanism in human and animal Enterobacteriaceae, with a wide geographical distribution and many producer strains resistant to multiple other antibiotics. mcr-1 encodes a membrane-bound enzyme catalysing phosphoethanolamine transfer onto bacterial lipid A. Here we present crystal structures revealing the MCR-1 periplasmic, catalytic domain to be a zinc metalloprotein with an alkaline phosphatase/sulphatase fold containing three disulphide bonds. One structure captures a phosphorylated form representing the first intermediate in the transfer reaction. Mutation of residues implicated in zinc or phosphoethanolamine binding, or catalytic activity, restores colistin susceptibility of recombinant E. coli. Zinc deprivation reduces colistin MICs in MCR-1-producing laboratory, environmental, animal and human E. coli. Conversely, over-expression of the disulphide isomerase DsbA increases the colistin MIC of laboratory E. coli. Preliminary density functional theory calculations on cluster models suggest a single zinc ion may be sufficient to support phosphoethanolamine transfer. These data demonstrate the importance of zinc and disulphide bonds to MCR-1 activity, suggest that assays under zinc-limiting conditions represent a route to phenotypic identification of MCR-1 producing E. coli, and identify key features of the likely catalytic mechanism.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28059088 PMCID: PMC5216409 DOI: 10.1038/srep39392
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Phosphoethanolamine Transfer Reaction Catalysed by MCR-1.
Panel shows hexa-acylated E. coli lipid A structure51 with 1′ and 4′ phosphate groups. MCR-1 catalyses transfer of phosphoethanolamine from a phosphatidylethanolamine donor substrate onto lipid A. Figure shows addition of phosphoethanolamine to the 1′ position of lipid A, consistent with the proposed activity of Salmonella PmrC14.
Figure 2Structure of MCR-1 Periplasmic Domain.
(A) Organisation of MCR-1 showing 5 predicted membrane-spanning α-helices and the soluble periplasmic domain (residues 219–541) crystallised here. (B) Overall fold of MCR-1 catalytic domain. Intramolecular disulphide bonds are labeled and metal centre (active site) is boxed. (C) Active site of P21 crystal form showing single bound zinc ion (grey sphere) and phosphorylation of Thr285. (D) Active site of P41212 crystal form showing dinuclear zinc centre and coordination of Zn2 by residue Glu300 (pink) from an adjacent molecule in the crystal lattice.
Figure 3Effect of Mutation and Zinc Deprivation upon MCR-1 Activity.
(A) MCR-1 active site (P21 crystal form) with colours identifying positions of alanine substitutions. (B) Effect of zinc deprivation on colistin Minimal Inhibitory Concentrations (MICs) for MCR-1-negative (12 isolates; blue) and MCR-1-expressing (68 isolates; red) E. coli. MICs were determined by broth microdilution in the presence and absence of EDTA (250 μg/ml) as described. (C) Colistin MICs (determined by agar dilution, data shown are modes for two independent experiments, each performed in duplicate) for alanine substitutions at positions shown in (A).
Figure 4Density Functional Theory (DFT) Modelling of the MCR-1 Active Site (Mono-zinc form).
(A) Possible mechanism for phosphoethanolamine addition (2) to MCR-1 Thr285 of mono-zinc MCR-1 (1) to form Thr285 adduct (3). (B) MCR-1 active site crystal structure (P21 form) showing residues used in cluster model. (C) DFT-optimised geometry of phosphoethanolamine non-covalently bound to MCR-1 active site (2 in panel (A) above). (D) DFT-optimised geometry of MCR-1 active site in the phosphoethanolamine-bound form (3 in panel (A) above). (See Supplementary Information for full computational details and a discussion of results).